Evidence map›Paper›PMID 31731605›Full record

ArticleNutrients2019

Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)

Mariska C Vlot, Laura Boekel, Jolijn Kragt, Joep Killestein, Barbara M van Amerongen, Robert de Jonge, Martin den Heijer, Annemieke C Heijboer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Free vitamin DEuropean journal of neurology · 2022
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mariska C VlotDepartment of Clinical Chemistry, Endocrine Laboratory, Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.
Laura BoekelDepartment of Clinical Chemistry, Endocrine Laboratory, Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.
Jolijn KragtDepartment of Neurology, Reinier de Graaf Gasthuis, 2625 AD Delft, The Netherlands.
Joep KillesteinDepartment of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam University Medical Center, 1081 HV, Amsterdam, The Netherlands.
Barbara M van AmerongenDepartment of Molecular Cell Biology and Immunology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
Robert de JongeDepartment of Clinical Chemistry, Endocrine Laboratory, Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.
Martin den HeijerDepartment of Internal Medicine, Amsterdam UMC, Amsterdam University medical Center, 1081 HV Amsterdam, The Netherlands.
Annemieke C HeijboerDepartment of Clinical Chemistry, Endocrine Laboratory, Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D (VitD) insufficiency is common in multiple sclerosis (MS). VitD has possible anti-inflammatory effects on the immune system. The ratio between VitD metabolites in MS patients and the severity of the disease are suggested to be related. However, the exact effect of the bone-derived hormone fibroblast-growth-factor-23 (FGF23) and VitD binding protein (VDBP) on this ratio is not fully elucidated yet. Therefore, the aim is to study differences in total, free, and bioavailable VD metabolites and FGF23 between MS patients and healthy controls (HCs). FGF23, vitD (25(OH)D), active vitD (1,25(OH)

Indexed as

25-Hydroxyvitamin D 2AdultBiological AvailabilityCase-Control StudiesErgocalciferolsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansMaleMiddle AgedMultiple SclerosisVitamin DVitamin D-Binding ProteinVitamin D Deficiency1,25-dihydroxyergocalciferol25-hydroxyvitamin D25-Hydroxyvitamin D 2ErgocalciferolsFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsGC protein, humanVitamin DVitamin D-Binding Proteinfibroblast growth factor 23multiple sclerosisvitamin D binding proteinvitamin D metabolites

Identifiers

PMID31731605
PMCPMC6893545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.